Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Cancer letters - 28 Jan 2017

Cholewa Brian D, Ndiaye Mary A, Huang Wei, Liu Xiaoqi, Ahmad Nihal

Abstract excerpt

The objective of this study was to determine the therapeutic potential of polo-like kinase 1 (Plk1) inhibition in melanoma, in vivo. Employing Vectra technology, we assessed the Plk1 expression profile in benign nevi, malignant (stages I-IV) and metastatic melanomas. We found a significant elevation of Plk1 immunostaining in melanoma tissues. Further, a second generation small molecule Plk1 inhibitor, BI 6727,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caspase 3
Share to Cyclin-Dependent Kinase Inhibitor p21

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to G2 Phase Cell Cycle Checkpoints

Share to Ki-67 Antigen

Share to Polo-Like Kinase 1

Share to Pteridines

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27793694
DOI: 10.1016/j.canlet.2016.10.025
PMCID: PMC5171235

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.PMID 27793694Read ↗

Polo-like kinase 1 (Plk1) in non-melanoma skin cancersSemantic proximity Read ↗

Polo-like kinase 1 is a potential therapeutic target in human melanoma.Semantic proximity Read ↗

Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma CellsSemantic proximity Read ↗

PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma PathwaysSemantic proximity Read ↗

Molecular approaches to tumor inhibition in melanoma.Semantic proximity Read ↗

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.Semantic proximity Read ↗

Targeting Polo-like Kinase in Cancer TherapySemantic proximity Read ↗

Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells.Semantic proximity Read ↗

B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.Semantic proximity Read ↗

Thoughts on the current assessment of Polo-like kinase inhibitor drug discoverySemantic proximity Read ↗

Physachenolide C induces complete regression of established murine melanoma tumors via apoptosis and cell cycle arrestSemantic proximity Read ↗

High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.